Gosset Ownership
Private
Employees
~7
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Temple Therapeutics General Information
Temple Therapeutics has completed a groundbreaking human trial for TTX333, which addresses post-surgical adhesions. The company is advancing this therapy through Phase 3 clinical trials for use in gynecological surgeries.
Contact Information
Drug Pipeline
Evitar
INDKey Partnerships
Temple Therapeutics Funding
No funding data available
To view Temple Therapeutics's complete valuation and funding history, request access »